Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

XOMA Corporation (XOMA) 4.11 -0.04
Price Open:4.10Day's Range:0.00000 - 4.93000
Price Close:4.1352wk Range:0.00000 - 4.93000
Price Day Change:-0.04Volume:435,522
Price % Change:-0.97Market Cap:339.0M
Bid:3.96000PE Ratio:0
Ask:4.11000EPS Diluted:-0.884
Trade XOMA NOW!

The Latest On XOMA

UPDATE: Canaccord Genuity Upgrades XOMA to Buy on Increased Confidence 5/9/13 10:11am
Benzinga's Top Upgrades 5/9/13 8:31am
XOMA Says Study Investigating Gevokizumab Opened for Enrollment 4/10/13 8:05am
Benzinga Market Primer: Tuesday, March 12 3/12/13 6:49am
Earnings Scheduled For March 12, 2013 3/12/13 4:41am
Benzinga's Top Pre-Market Losers 2/4/13 9:22am
UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy 1/7/13 3:14pm
XOMA Offers Encouraging Interim Results from Gevokizumab Phase 2 Study 1/7/13 9:03am
XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients 11/29/12 9:25am
UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential 11/13/12 2:44pm
XOMA Prices 13.33M Shares at $3 Each 10/24/12 8:59am
XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis 9/27/12 1:15pm
more
Press Releases
XOMA Highlights Recent Achievements and Reports Financial Results for First Quarter 2013 5/8/13 GlobeNewswire
XOMA to Present at Credit Suisse 2013 Antibody Day 5/6/13 GlobeNewswire
XOMA to Announce First Quarter 2013 Financial Results and Host Webcast on May 8 4/25/13 GlobeNewswire
XOMA Announces Clinical Study Investigating Gevokizumab in Patients With Non-Infectious Anterior Scleritis Has Opened for Enrollment at the National Eye Institute 4/10/13 GlobeNewswire
XOMA Appoints Tom Klein to Newly Created Position of Chief Commercial Officer 3/18/13 GlobeNewswire
XOMA Reports 2012 Operational Highlights and Fourth Quarter and Full-Year Financial Results 3/12/13 GlobeNewswire
XOMA Announces Fourth Quarter and Full-Year Financial Results Conference Call 3/4/13 GlobeNewswire
XOMA to Present at Upcoming Investor Conferences 2/21/13 GlobeNewswire
XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris 1/7/13 GlobeNewswire
XOMA Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program 12/31/12 GlobeNewswire
XOMA Appoints Joseph M. Limber to Its Board of Directors 12/13/12 GlobeNewswire
XOMA Announces Servier Has Initiated a Proof-of-Concept Gevokizumab Study in Patients With a History of Acute Coronary Syndrome 11/29/12 GlobeNewswire

Get the latest XOMA stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for XOMA Corporation stock price.

Partner Headlines
Positive Data on Celgene's Apremilast - Analyst Blog 5/9/13
ARNA Sheds Light on Belviq Launch - Analyst Blog 5/9/13
VIVUS Reports Wider Loss - Analyst Blog 5/9/13
CHMP Backs VIVUS' Spedra - Analyst Blog 4/30/13
Bayer Earnings Rise Y/Y - Analyst Blog 4/26/13
AstraZeneca Earnings Tumble Y/Y - Analyst Blog 4/26/13
AZN/BIND Therapeutics Ink Deal - Analyst Blog 4/23/13
Illumina Beats on Earnings, Revenue - Analyst Blog 4/23/13
AZN Inks Biomarker Discovery Deal - Analyst Blog 4/18/13
Spectrum Progresses with SPI-2012 - Analyst Blog 4/9/13
Illumina Introduces TruSight Tumor - Analyst Blog 4/8/13
Balanced View on Gilead Sciences - Analyst Blog 3/28/13